TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

65 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

56 studies on the map

Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — Arizona Liver Health, ChandlerEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Perseverance Research Center, ScottsdaleA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — GSK Investigational Site, ArcadiaStudy to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder — Vanda Investigational Site, PhoenixStudy to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — TG Therapeutics Investigational Trial Site, BirminghamAn Open-label Study of AZD0120 in Adults With Multiple Sclerosis — Research Site, TucsonACT for Individuals With MNCD and Their Care Partners — Texas Tech University Plaza Building, LubbockA Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases — Stanford Neuroscience Health Center, Palo AltoA Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis — Stanford Multiple Sclerosis Center, Palo AltoNebulized Ketamine for the Treatment of Major Depressive Disorder — Maimonides Medical Center, BrooklynA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PheonixCreatine for Depressed Male and Female Methamphetamine Users — Montana State University College of Nursing (Missoula campus), MissoulaBest Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) — Stanford Multiple Sclerosis Center, Palo AltoA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis — Akero Clinical Study Site, BirminghamA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) — 89bio Clinical Study Site, BirminghamHuman Models of Selective Insulin Resistance: Alpelisib, Part I — Columbia University Irving Medical Center, New YorkA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PhoenixA Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis — Stanford University Medical Center, StanfordStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis — Local Institution - 0114, Loma LindaTreatment of Participants With Primary or Secondary Progressive Multiple Sclerosis — University of Kansas Medical Center, Kansas CityA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH — 89bio Clinical Study Site, BirminghamA Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) — Local Institution - 0011, BirminghamOpen-Label Psilocybin Study in Transdiagnostic Population — Connecticut Mental Health Center - Yale School of Medicine, New HavenExploring the Utility of [18F]3F4AP for Demyelination Imaging — Yale University PET Center, New HavenUse of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use — 46 Centerra Parkway, Suite 300, Office #333S, LebanonThe Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety — The Ohio State University, ColumbusA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Alabama Neurology Associates PC, BirminghamEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) — UC San Diego, San DiegoEvaluating the Pharmacokinetics and Safety of Miricorilant — Site# 433, San AntonioBicalutamide Therapy in Young Women With NAFLD and PCOS — University of California San Francisco, San FranciscoCannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder — Wayne State University School of Medicine, Tolan Park Medical Building, DetroitObe-cel in Refractory Progressive Forms of Multiple Sclerosis — Stanford University, Redwood CityAssessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy — Sandler Neurosciences Building, Neurological Clinical Research Unit, San FranciscoNon-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis — University of Washington, SeattleA Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis — Profound Research, LLC, CarlsbadA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH — Akero Clinical Study Site, BirminghamAssessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. — University of Alabama at Birmingham Medical Center, BirminghamLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH — GSK Investigational Site, ArcadiaSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis — North Central Neurology Associates- Site Number : 8401100, CullmanA Study of Efimosfermin Alfa in Adults With Hepatic Impairment — GSK Investigational Site, RialtoEffect of Insulin Lowering on Lipogenesis — Columbia University Irving Medical Center, New YorkCentral Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy — National Institutes of Health Clinical Center, BethesdaEffect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) — Univeristy of Colorado Anschutz Medical Campus, AuroraPET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases — Brigham MS Center, 60 Fenwood Road, BostonTargeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) — National Institutes of Health Clinical Center, BethesdaMolecular Imaging of NET Using [C-11]MRB-PET in MS — Brigham MS Center, 60 Fenwood Road, BostonTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamInvestigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects — Massachusetts General Hospital, BostonEstrogen Administration for the Treatment of NASH in Postmenopausal Women — Massachusetts General Hospital, BostonCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer — MD Anderson Cancer Center, HoustonVancomycin Study in Multiple Sclerosis (MS) — Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New YorkEvaluation of Miricorilant on Liver Fat in Patients With MASLD — University of Missouri, Columbia